Noom Review
Best for: mainstream telehealth GLP-1 access
Behavioral weight loss app that also offers GLP-1 prescriptions through Noom Med.
What the monthly price covers
Medication
Not disclosed
Provider visits
Included
Shipping
Not disclosed
Lab work
Not disclosed
Coaching
Included
No insurance needed · Vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Noom is a solid telehealth option with balanced features and pricing.
Noom at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- What's included
- Consult · Coaching
- FDA status
- No FDA warning letter on record
How we scored Noom
Each dimension is scored algorithmically from Noom’s real pricing, drugs offered, verification status, and disclosed inclusions — using the same six-dimension framework we apply to every provider.
Value25%
6.3/10Noom does not post a standard monthly cash price up front, so cost transparency is limited — confirm the ongoing rate before you commit.
Effectiveness25%
8.1/10Noom offers both semaglutide and tirzepatide — the two GLP-1 molecules with the strongest published weight-loss trial outcomes.
User Experience15%
7.1/10Online intake and platform experience — consult included in the price; 2 platform features disclosed.
Trust & Safety15%
7.3/10Core details confirmed by our editors; no FDA warning letters on file (last checked 2026-06-03).
Accessibility10%
6.1/10Noom's exact state footprint isn't published — confirm coverage in your state before signing up.
Support10%
7.2/10Coaching/dietitian access included.
How we verified this Noom review
Last checked 2026-06-03- Confirmed what the monthly price does and doesn't include
- Checked the FDA warning-letter database for enforcement actions
- Walked the public intake/checkout flow on the provider's site
Pricing, availability, and compliance facts come from the provider's own site and primary regulatory records — see the sources below. Editorial confidence in this data: medium.
GLP-1 medications Noom offers
Tap any medication to read our plain-English guide — how it works, dosing, side effects, and what the trials found.
What we like
- Both semaglutide and tirzepatide available
Watch-outs
- Pricing not publicly disclosed
Noom Med: the weight-loss app that grew a prescription pad
Most people meet Noom long before they think about a GLP-1. It started as the psychology-driven food-logging app with the cheerful color-coded meals and the daily coaching nudges, and that history is the single most important thing to understand about it. Noom Med is the clinical add-on bolted onto a behavior-change platform, not a standalone telehealth pharmacy. If you want a medication and nothing else, Noom is an odd fit. If you want a semaglutide or tirzepatide prescription wrapped inside a structured habit program you'll actually use, that combination is exactly what it's built to sell.
What you can actually be prescribed
Noom Med is unusually broad on the medication side. Our 2026 verification of noom.com/med found it prescribing the full slate of brand-name GLP-1s — Wegovy, Zepbound, Ozempic, and Mounjaro — plus the oral Wegovy pill and plain metformin for people who want to start gentler or cheaper. On top of that it offers a compounded "Microdose GLP-1" track and a separate brand-name access path. That's a wider menu than many app-first competitors, which tend to push one compounded formulation and call it a day.
- Brand-name injectables: Wegovy, Zepbound, Ozempic, Mounjaro
- Oral options: the Wegovy pill and metformin
- Compounded route: a low-dose "Microdose GLP-1" plan as a lower-cost entry point
How the pricing really works — and why we can't quote you a flat number
Here's the honest catch. Noom does not publish a single, clean monthly medication price the way a cash-pay clinic does, and our editor-verified record carries no standard rate we're willing to stand behind. Instead the cost splits by which path you pick: the compounded microdose plan is priced as a low monthly access fee, while the brand-name route charges a smaller access fee plus the actual cost of the medication, which is the part that does the real damage to your wallet. Treat any figure you see in an ad as plan-dependent, not a guaranteed all-in price.
Because the model is layered like this, the only safe move is to run your own numbers inside the app before committing. Confirm the current access fee for your chosen path, then confirm what the medication itself costs on top of it. For context, our category median sits around $170, but Noom's split-fee structure means your real total could land well under or well over that depending on whether you go compounded or brand. Compare the all-in figure against our scoring methodology and against a flat-rate competitor before you sign up.
The coaching is the differentiator, not the pharmacy
Strip away the medication and what's left is still a serious product, and that's the point. Every medication plan includes full access to the core Noom app, plus what the company describes as on-demand one-to-one support and coaching and unlimited chat with its doctors. For someone who has rebounded after past diets, that wraparound — the logging, the lessons, the human in your pocket when a craving hits at nine at night — is the genuine reason to pick Noom over a bare-bones script mill. The drug suppresses appetite; the app is supposed to rebuild the habits so the loss sticks when you eventually taper off.
Who should choose Noom — and who should walk
Choose Noom if you're a mainstream patient who wants the medication and the behavioral scaffolding in one subscription, and who finds app-based accountability genuinely helpful. It's a comfortable on-ramp for first-timers who'd rather not assemble a clinic, a coach, and a pharmacy separately.
- Good fit: people who want medication plus structured habit coaching, GLP-1 first-timers, anyone who already likes the Noom app
- Poor fit: price-shoppers who want one flat, transparent monthly number; people who only want a prescription with no app or coaching attached; anyone who dislikes daily-engagement programs
Trust, oversight, and the gaps we'd flag
Noom carries no FDA warning letters in our file, and it's a large, well-known consumer-health company rather than a fly-by-night brand — both points in its favor. But two transparency gaps keep it from a top-tier confidence rating. First, it does not publicly disclose which states it serves, so you have to confirm coverage in your own state before assuming you can sign up. Second, the opaque, plan-dependent pricing means cost only becomes clear once you're inside the funnel. Neither is a safety red flag; both are friction you should know about going in.
The bottom line
Noom Med is a credible, broad-menu GLP-1 option whose real value is the behavior-change program around the prescription, not a bargain price. If you want the app-plus-medication bundle and you're willing to verify your state and total cost yourself before paying, it's a reasonable mainstream pick. If you just want the cheapest transparent script, a flat-rate cash-pay competitor will serve you better. Confirm the live access fee and the medication cost for your specific plan before you commit — Noom's published numbers shift, so the figure you check today is the only one that counts.
For a side-by-side, Telos Rx ($49/month) and bmiMD ($99/month) are the most comparable options to weigh against Noom.
Ready to start with Noom?
See current pricing and start your free consultation.
Alternatives to Noom
Enhance MD
Best for: lab-monitored compounded GLP-1 with mandatory video visit
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
The primary regulatory filings and peer-reviewed studies cited throughout this Noom review:
Sources & methodology — as of July 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
Ready to start with Noom?
See current pricing and start your free consultation.